logo
logo
EYPT stock ticker logo

EyePoint Pharmaceuticals, Inc.

NASDAQ•EYPT
CEO: Dr. Jay S. Duker M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2005-01-27
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Contact Information
480 Pleasant Street, Suite A-210, Watertown, MA, 02472, United States
617-926-5000
eyepointpharma.com
Market Cap
$1.24B
P/E (TTM)
-5.3
17.4
Dividend Yield
--
52W High
$19.11
52W Low
$3.91
52W Range
72%
Rank67Top 97.6%
1.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$620.00K+0.00%
4-Quarter Trend

EPS

-$0.81+0.00%
4-Quarter Trend

FCF

-$66.03M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Royalty Income Surge Royalty income increased 708% to $13.04M due to ANI buyout of ILUVIEN/YUTIQ royalty obligation in March 2025.
DURAVYU Phase 3 Enrollment Complete Enrollment finalized for wet AMD Phase 3 trials (LUGANO/LUCIA); data anticipated beginning mid-2026 for lead candidate.
Strong Cash Position Maintained Cash reserves totaled $306.1M as of December 31, 2025, funding operations into the fourth quarter of 2027.
R&D Spending Ramps Up Research and development expenses rose 66% to $221.04M, driven by ongoing DURAVYU Phase 3 clinical trials.

Risk Factors

Operating Losses Deepen Net loss widened 77% to $231.96M in 2025; continued operating losses expected for foreseeable future.
DURAVYU Approval Uncertainty Business heavily dependent on DURAVYU success; clinical trial outcomes remain uncertain, potentially delaying approval.
Need Additional Capital Additional capital required for development; future fundraising may be dilutive or impose operational restrictions.
DOJ Settlement Compliance Costs Finalizing $4.7M DOJ settlement requires Corporate Integrity Agreement, imposing significant future compliance costs.

Outlook

Anticipated DURAVYU Data Expecting wet AMD Phase 3 pivotal data starting mid-2026; DME Phase 3 dosing initiated Q1 2026.
Commercial Manufacturing Scale Tech transfer ongoing to Northbridge facility to support potential DURAVYU commercial launch post-approval.
Advance EYP-2301 Development Advancing pipeline asset EYP-2301 into preclinical development, focusing on toxicity and pharmacokinetic studies.
Focus on Commercial Readiness Strategy centers on advancing DURAVYU through Phase 3, preparing for potential US commercial launch.

Peer Comparison

Revenue (TTM)

ANAB stock ticker logoANAB
$234.60M
+157.0%
MRVI stock ticker logoMRVI
$185.74M
-28.3%
PHAT stock ticker logoPHAT
$175.11M
+216.9%

Gross Margin (Latest Quarter)

ANAB stock ticker logoANAB
199.8%
+99.5pp
KURA stock ticker logoKURA
97.3%
+0.0pp
XNCR stock ticker logoXNCR
90.9%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TNGX$1.97B-19.4-50.3%8.4%
ANAB$1.86B-135.81813.8%79.8%
NRIX$1.38B-5.7-57.5%8.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-70.6%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Deep Research

Next earnings:May 5, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data